Published in J Clin Invest on July 01, 1990
Conversion of Pseudomonas aeruginosa to mucoidy in cystic fibrosis: environmental stress and regulation of bacterial virulence by alternative sigma factors. J Bacteriol (1994) 3.15
Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest (1992) 2.62
Antibacterial activity of antileukoprotease. Infect Immun (1996) 2.48
Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest (1992) 2.33
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest (2002) 2.19
State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res (2003) 1.86
Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax (2001) 1.48
Nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. Infect Immun (1995) 1.45
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
Human leukocyte elastase is an endogenous ligand for the integrin CR3 (CD11b/CD18, Mac-1, alpha M beta 2) and modulates polymorphonuclear leukocyte adhesion. J Exp Med (1996) 1.30
Proteases and cystic fibrosis. Int J Biochem Cell Biol (2008) 1.25
Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. Am J Respir Cell Mol Biol (2003) 1.14
Lung infections. 3. Pseudomonas aeruginosa and other related species. Thorax (1998) 1.08
Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun (1994) 1.07
Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Mol Med (2010) 0.97
Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax (1995) 0.95
RpmA is required for nonopsonic phagocytosis of Pseudomonas aeruginosa. Infect Immun (2000) 0.93
Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Infect Immun (2001) 0.92
Factors influencing airway inflammation in chronic obstructive pulmonary disease. Thorax (2000) 0.92
Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros (2005) 0.88
Neutrophil elastase converts human immature dendritic cells into transforming growth factor-beta1-secreting cells and reduces allostimulatory ability. Am J Pathol (2007) 0.88
Reduced iC3b-mediated phagocytotic capacity of pulmonary neutrophils in cystic fibrosis. Clin Exp Immunol (2005) 0.88
Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester. J Clin Invest (1994) 0.86
Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. Am J Respir Crit Care Med (2009) 0.86
Complement Effectors of Inflammation in Cystic Fibrosis Lung Fluid Correlate with Clinical Measures of Disease. PLoS One (2015) 0.83
Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats. Clin Exp Immunol (2015) 0.82
Effects of mucoid and non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients on inflammatory mediator release from human polymorphonuclear granulocytes and rat mast cells. Immunology (1992) 0.81
Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun (2016) 0.79
Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes. J Diabetes Sci Technol (2014) 0.78
Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes. Ther Clin Risk Manag (2015) 0.78
The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis Lung. Mediators Inflamm (2015) 0.78
Influence of neutrophil defects on Burkholderia cepacia complex pathogenesis. Front Cell Infect Microbiol (2011) 0.78
Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease. Mol Cell Pediatr (2016) 0.77
Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Clin Exp Immunol (2004) 0.77
Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants. Am J Physiol Lung Cell Mol Physiol (2015) 0.77
SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition. Eur Respir J (2010) 0.76
Pharmacological activities of TEI-8362, a novel inhibitor of human neutrophil elastase. Br J Pharmacol (1999) 0.76
New treatments in adult cystic fibrosis. J R Soc Med (1997) 0.75
A new assay to monitor the degranulation process in phagocytizing human neutrophils. Inflammation (2002) 0.75
Neutrophil Elastase Activity is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. Am J Respir Crit Care Med (2016) 0.75
Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest (1973) 17.56
Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis (1985) 3.61
Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis (1985) 3.28
Pulmonary alveolar macrophage. Defender against bacterial infection of the lung. J Clin Invest (1974) 3.22
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis (1985) 2.04
The inhibition of phagocytosis and facilitation of exocytosis in rabbit polymorphonuclear leukocytes by cytochalasin B. Lab Invest (1973) 1.89
Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol (1984) 1.87
Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest (1984) 1.86
Identification of a second class of IgG Fc receptors on human neutrophils. A 40 kilodalton molecule also found on eosinophils. J Exp Med (1986) 1.82
Functional differences between the 40 kDa and 50 to 70 kDa IgG Fc receptors on human neutrophils revealed by elastase treatment and antireceptor antibodies. J Immunol (1988) 1.48
Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest (1989) 1.44
Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis. Infect Immun (1985) 1.41
Cystic fibrosis. J Clin Invest (1987) 1.24
Lucigenin-dependent chemiluminescence as a new assay for NAD(P)H-oxidase activity in particulate fractions of human polymorphonuclear leukocytes. J Immunol Methods (1984) 1.16
A quantitative method for assessing the third complement factor (C3) attached to the surface of opsonized Pseudomonas aeruginosa: interrelationship between C3 fixation, phagocytosis and complement consumption. J Immunol Methods (1985) 1.14
Increased expression of complement decay-accelerating factor during activation of human neutrophils. J Clin Invest (1987) 1.13
Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med (1986) 1.11
Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease. Clin Exp Immunol (1986) 1.07
Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from sputum of cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand C (1984) 1.07
A quantitative fluorescent method for measurement of bacterial adherence and phagocytosis. J Immunol Methods (1986) 1.07
Kinetic studies of neutrophil phagocytosis. V. studies on the co-operation between the Fc and C3b receptors. Immunology (1982) 0.99
Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. Pediatr Res (1986) 0.98
Effect of piliation on interactions of Haemophilus influenzae type b with human polymorphonuclear leukocytes. Infect Immun (1985) 0.92
Interactions of Pseudomonas aeruginosa with immunoglobulins and complement in sputum. Infect Immun (1976) 0.91
Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis. J Infect Dis (1988) 0.88
Cleavage of C3 by neutral proteases from granulocytes in pleural empyema. J Infect Dis (1981) 0.87
Cleavage of membrane bound C3bi, an intermediate of the third component of complement, to C3c and C3d-like fragments by crude leucocyte lysosomal lysates and purified leucocyte elastase. Immunology (1981) 0.87
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Cortical language localization in left, dominant hemisphere. An electrical stimulation mapping investigation in 117 patients. J Neurosurg (1989) 4.18
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Attainment and adjustment in two geographical areas. I--The prevalence of psychiatric disorder. Br J Psychiatry (1975) 3.79
Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation (1990) 3.52
Hypoglycemic symptoms and frequency of severe hypoglycemia in patients treated with human and animal insulin preparations. Diabetes Care (1991) 3.51
Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol (1985) 3.50
Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med (1995) 3.47
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med (1994) 3.24
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem (2000) 2.71
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care (1987) 2.50
Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med (1999) 2.36
Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia (1983) 2.18
Sleep and depression--results from psychobiological studies: an overview. Biol Psychol (2001) 2.02
Effect of age on excess mortality in obesity. JAMA (1999) 2.01
Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia (1997) 1.95
Oxidative damage to DNA: formation, measurement, and biological significance. Rev Physiol Biochem Pharmacol (1997) 1.91
The formation of glutamine and alanine in skeletal muscle. J Biol Chem (1974) 1.90
Glucose metabolism in perfused skeletal muscle. Effects of starvation, diabetes, fatty acids, acetoacetate, insulin and exercise on glucose uptake and disposition. Biochem J (1976) 1.90
Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest-Düsseldorf Study. Diabetologia (1987) 1.87
Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia (1990) 1.84
Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol (1995) 1.82
Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J (1974) 1.78
Glucose metabolism in perfused skeletal muscle. Interaction of insulin and exercise on glucose uptake. Biochem J (1975) 1.71
Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol (1997) 1.68
Effective and safe translation of intensified insulin therapy to general internal medicine departments. Diabetologia (1993) 1.67
Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care (1985) 1.67
Issues in the measurement of satisfaction with treatment. Am J Manag Care (1997) 1.67
Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis (1995) 1.63
Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains. J Cell Biol (1998) 1.63
Assessment of excess mortality in obesity. Am J Epidemiol (1998) 1.62
Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci (1993) 1.61
Glucose metabolism in rat skeletal muscle at rest. Effect of starvation, diabetes, ketone bodies and free fatty acids. Diabetes (1974) 1.61
Health beliefs and compliance with inhaled corticosteroids by asthmatic patients in primary care practices. Respir Med (1999) 1.59
Lack of binding of human C3, in its native state, to C3b receptors. J Immunol (1981) 1.57
Evaluation of a structured treatment and teaching programme on non-insulin-dependent diabetes. Lancet (1988) 1.56
Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study. J Pediatr (1989) 1.53
The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol (1997) 1.52
Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect Immun (1983) 1.51
Prevalence of insomnia in elderly general practice attenders and the current treatment modalities. Acta Psychiatr Scand (1994) 1.51
Uncontrolled-rate freezing and storage at -80 degrees C, with only 3.5-percent DMSO in cryoprotective solution for 109 autologous peripheral blood progenitor cell transplantations. Transfusion (2001) 1.51
Noninvasive estimation of pulmonary artery diastolic pressure in patients with tricuspid regurgitation by Doppler echocardiography. Chest (1999) 1.51
Action profiles of fast onset insulin analogues. Diabetologia (1990) 1.50
Obstructive sleep apnea is a risk factor for difficult endotracheal intubation. Minerva Anestesiol (2011) 1.49
Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood (1997) 1.48
Echocardiographic detection of transient right heart thrombus: now you see it, now you don't. Am Heart J (1991) 1.48
Unsuspected cardiac abnormalities in the acquired immune deficiency syndrome. An echocardiographic study. Chest (1989) 1.48
Functional differences between the 40 kDa and 50 to 70 kDa IgG Fc receptors on human neutrophils revealed by elastase treatment and antireceptor antibodies. J Immunol (1988) 1.48
Test-retest reliability and validity of the Structured Interview for Sleep Disorders According to DSM-III-R. Am J Psychiatry (1993) 1.46
Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis (1988) 1.45
Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin Invest (1988) 1.42
Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Diabetologia (1997) 1.42
Captopril, blood pressure, and diabetic nephropathy. JAMA (1994) 1.42
[Chronic fatigue syndrome. Definition, diagnostic measures and therapeutic possibilities]. Nervenarzt (1996) 1.42
Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med (1996) 1.41
Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci (1997) 1.41
Hemodialysis of children: a review. Tex Med (1976) 1.40
Diabetes care in cats and dogs. Diabet Med (2002) 1.39
[Significance of historical and current hallucinogenic research in psychiatry]. Nervenarzt (1993) 1.39
[Differential indications for psychotherapy exemplified by depression]. Nervenarzt (2011) 1.39
[The metabolic effects of beta-receptor blockers. What is of practical importance in antihypertensive therapy?]. Dtsch Med Wochenschr (1992) 1.39
Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med (1992) 1.38
HLA-DR2 and sleep onset REM periods in endogenous depression. Br J Psychiatry (1988) 1.38
Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol (1999) 1.38
Reliability of causes of death in persons with Type I diabetes. Diabetologia (2002) 1.38
[Addressed to the Federal Professional Society of Rehabilitation on "Planning ambulatory rehabilitation of psychosomatic and psychiatric diseases" 15 January 2003]. Nervenarzt (2003) 1.37
Complement receptors. Clin Immunol Rev (1983) 1.37
Radiation-induced decomposition of the purine bases within DNA and related model compounds. Int J Radiat Biol Relat Stud Phys Chem Med (1985) 1.36
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol (2012) 1.36
Functional and molecular aspects of voltage-gated K+ channel beta subunits. Ann N Y Acad Sci (1999) 1.34
Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett (1991) 1.34
Exercise and diabetes mellitus. Diabetes (1979) 1.34
Exercise-induced fall of blood glucose in insulin-treated diabetics unrelated to alteration of insulin mobilization. Diabetes (1979) 1.33
Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect Immun (1983) 1.31
Noncontact fluorescence diffuse optical tomography of heterogeneous media. Appl Opt (2007) 1.31
Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest (1992) 1.28
Studies on the mechanism of T cell inhibition by the Pseudomonas aeruginosa phenazine pigment pyocyanine. J Immunol (1987) 1.27
Mycobacterium tuberculosis 19-kDa lipoprotein promotes neutrophil activation. J Immunol (2001) 1.26
A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4. J Immunol (1984) 1.26
Cigarette-smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes. Diabetologia (1986) 1.26
The nephrotic syndrome secondary to acute glomerulonephritis during falciparum malaria. Ann Intern Med (1967) 1.25
Systematic review and validation of prediction rules for identifying children with serious infections in emergency departments and urgent-access primary care. Health Technol Assess (2012) 1.25
Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia (1994) 1.25
Attainment and adjustment in two geographical areas: III--Some factors accounting for area differences. Br J Psychiatry (1975) 1.25
Molecular cloning and characterization of murine and human N-acetylglucosamine kinase. Eur J Biochem (2000) 1.25
E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ (2009) 1.24
Patient education as the basis for diabetes care in clinical practice and research. Diabetologia (1985) 1.24
Prevalence of renal artery stenosis in diabetes mellitus--an autopsy study. J Intern Med (1991) 1.24
Attainment and adjustment in two geographical areas. II--The prevalence of specific reading retardation. Br J Psychiatry (1975) 1.24
Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. Diabetes Care (1998) 1.23
Patient education - evaluation of a complex intervention. Diabetologia (2002) 1.23
Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med (1995) 1.23
Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia (1984) 1.23
Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med (1980) 1.23
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics. J Med Chem (2008) 1.22
Absorption kinetics of subcutaneously injected insulin. Evidence for degradation at the injection site. Diabetologia (1979) 1.22
Case-control study on stomach cancer in Germany. Int J Cancer (1991) 1.22